US 12,467,089 B2
Molecular signatures of three sub-populations of dermal fibroblasts and dermal equivalent comprising one of these sub-populations
Valérie Haydont, Aulnay-sous-Bois (FR); and Daniel Asselineau, Aulnay-sous-Bois (FR)
Assigned to L'OREAL, Paris (FR)
Appl. No. 16/650,258
Filed by L'OREAL, Paris (FR)
PCT Filed Sep. 27, 2018, PCT No. PCT/EP2018/076347
§ 371(c)(1), (2) Date Mar. 24, 2020,
PCT Pub. No. WO2019/063731, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. 1759026 (FR), filed on Sep. 28, 2017.
Prior Publication US 2021/0371925 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6881 (2018.01); C12N 5/077 (2010.01)
CPC C12Q 1/6881 (2013.01) [C12N 5/0656 (2013.01); C12Q 2600/158 (2013.01)] 12 Claims
 
1. A method of preparing a dermal equivalent comprising a sub-population of dermal-hypodermal junction fibroblasts (FJDH) comprising:
(a) providing a biological sample comprising dermal fibroblasts;
(b) sampling a first portion of the biological sample provided in step (a);
(c) measuring the level of COL11A1, UCP2, and KLF9 in the first portion;
(d) determining that the first portion comprises FJDH when (i) the level of COL11A1 is higher than the level of COL11A1 in a reference sample of papillary fibroblasts, (ii) the level of UCP2 is lower than the level of UCP2 in a reference sample of papillary fibroblasts, and (iii) the level of KLF9 is higher than the level of KLF9 in a reference sample of reticular fibroblasts; and
(e) using a unsampled portion of the biological sample provided in step (a) to prepare a dermal equivalent comprising a sub-population of FJDH.